메뉴 건너뛰기




Volumn 54, Issue 1, 2006, Pages 47-54

Combination of anabolic and antiresorptive agents for the treatment of osteoporosis

Author keywords

Bone forming agents; Combination therapy; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; ETIDRONIC ACID; FLUORIDE; PARATHYROID HORMONE; PLACEBO; RALOXIFENE; RISEDRONIC ACID;

EID: 33645099604     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2005.08.011     Document Type: Article
Times cited : (14)

References (38)
  • 1
    • 0000664911 scopus 로고    scopus 로고
    • Diagnosis and therapy osteoporosis prevention, Diagnosis and Therapy
    • NIH Consensus development panel on osteoporosis prevention. Diagnosis and therapy osteoporosis prevention, Diagnosis and Therapy. JAMA 2001; 285, 785-795.
    • (2001) JAMA , vol.285 , pp. 785-795
  • 2
    • 0037042498 scopus 로고    scopus 로고
    • Treatment of postmenopausal osteoporosis
    • P.D. Delmas Treatment of postmenopausal osteoporosis Lancet 359 2002 2018 2026
    • (2002) Lancet , vol.359 , pp. 2018-2026
    • Delmas, P.D.1
  • 3
    • 9144233479 scopus 로고    scopus 로고
    • The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis
    • P.J. Meunier, C. Roux, and E. Seeman The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 5 2004 459 468
    • (2004) N Engl J Med , vol.350 , Issue.5 , pp. 459-468
    • Meunier, P.J.1    Roux, C.2    Seeman, E.3
  • 4
    • 0029055554 scopus 로고
    • Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: 4 year randomized study
    • S.J. Wimalawansa Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: 4 year randomized study Am J Med 99 1995 36 42
    • (1995) Am J Med , vol.99 , pp. 36-42
    • Wimalawansa, S.J.1
  • 5
    • 0032033065 scopus 로고    scopus 로고
    • A 4-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis
    • S.J. Wimalawansa A 4-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis Am J Med 104 1998 219 226
    • (1998) Am J Med , vol.104 , pp. 219-226
    • Wimalawansa, S.J.1
  • 6
    • 0033304521 scopus 로고    scopus 로고
    • Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial
    • R. Lindsay, F. Cosman, and R.A. Lobo Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial J Clin Endocrinol Metab 84 1999 3076 3081
    • (1999) J Clin Endocrinol Metab , vol.84 , pp. 3076-3081
    • Lindsay, R.1    Cosman, F.2    Lobo, R.A.3
  • 7
    • 17744392399 scopus 로고    scopus 로고
    • Alendronate and estrogen effects in postmenopausal women with low bone mineral density
    • H.G. Bone, S.L. Greenspan, and C. McKeever Alendronate and estrogen effects in postmenopausal women with low bone mineral density J Clin Endocrinol Metab 85 2000 720 726
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 720-726
    • Bone, H.G.1    Greenspan, S.L.2    McKeever, C.3
  • 8
    • 0037016032 scopus 로고    scopus 로고
    • Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis
    • S.L. Greenspan, R.E. Emkey, and H.G. Bone Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis Ann Intern Med 137 2002 875 883
    • (2002) Ann Intern Med , vol.137 , pp. 875-883
    • Greenspan, S.L.1    Emkey, R.E.2    Bone, H.G.3
  • 9
    • 0034999663 scopus 로고    scopus 로고
    • Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women
    • S.T. Harris, E.F. Eriksen, and M. Davidson Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women J Clin Endocrinol Metab 86 2001 1890 1897
    • (2001) J Clin Endocrinol Metab , vol.86 , pp. 1890-1897
    • Harris, S.T.1    Eriksen, E.F.2    Davidson, M.3
  • 10
    • 0036963450 scopus 로고    scopus 로고
    • Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis
    • O. Johnell, W.H. Scheele, J.Y. Reginster, A.G. Need, and E. Seeman Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis J Clin Endocrinol Metab 87 2002 985 992
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 985-992
    • Johnell, O.1    Scheele, W.H.2    Reginster, J.Y.3    Need, A.G.4    Seeman, E.5
  • 11
    • 0037974904 scopus 로고    scopus 로고
    • Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women
    • S.L. Greenspan, N.M. Resnik, and R.A. Parker Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women JAMA 289 2003 2525 2533
    • (2003) JAMA , vol.289 , pp. 2525-2533
    • Greenspan, S.L.1    Resnik, N.M.2    Parker, R.A.3
  • 13
    • 0038796585 scopus 로고    scopus 로고
    • Treatment of osteoporosis: Combination therapies
    • J.A. Simon, and C.J. Mack Treatment of osteoporosis: combination therapies Int J Fertil 48 2003 127 131
    • (2003) Int J Fertil , vol.48 , pp. 127-131
    • Simon, J.A.1    MacK, C.J.2
  • 14
    • 0036268714 scopus 로고    scopus 로고
    • Combination therapy for postmenopausal osteoporosis
    • J.E. Compston, and N.B. Watts Combination therapy for postmenopausal osteoporosis Clin Endocrinol 56 2002 565 569
    • (2002) Clin Endocrinol , vol.56 , pp. 565-569
    • Compston, J.E.1    Watts, N.B.2
  • 15
    • 0036962096 scopus 로고    scopus 로고
    • Editorial: For osteoporosis, are two antiresorptive drugs better than one?
    • Ettinger B, Bilezikian JP. Editorial: For osteoporosis, are two antiresorptive drugs better than one? J Clin Endocrinol Metab 2002; 87:983-984.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 983-984
    • Ettinger, B.1    Bilezikian, J.P.2
  • 16
    • 0033669403 scopus 로고    scopus 로고
    • Fluoride for the treatment of postmenopausal osteoporotic fractures: A meta-analysis
    • D. Haguenauer, V. Welch, B. Shea, P. Tugwell, J.D. Adachi, and G. Wells Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis Osteopor Int 11 2000 727 738
    • (2000) Osteopor Int , vol.11 , pp. 727-738
    • Haguenauer, D.1    Welch, V.2    Shea, B.3    Tugwell, P.4    Adachi, J.D.5    Wells, G.6
  • 17
    • 0033305354 scopus 로고    scopus 로고
    • Monofluorphosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: A randomized study
    • P. Alexandersen, B.J. Riis, and C. Christiansen Monofluorphosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study J Clin Endocrinol Metab 84 1999 3013 3020
    • (1999) J Clin Endocrinol Metab , vol.84 , pp. 3013-3020
    • Alexandersen, P.1    Riis, B.J.2    Christiansen, C.3
  • 18
    • 18344380632 scopus 로고    scopus 로고
    • A randomized trial of sodium fluoride (60 mg) ± estrogen in postmenopausal osteoporotic vertebral fractures: Increased vertebral fractures and peripheral bone loss with sodium fluoride; Concurrent estrogen prevents peripheral loss, but not vertebral fractures
    • D.H. Guteridge, G.O. Stewart, and R.L. Prince A randomized trial of sodium fluoride (60 mg) ± estrogen in postmenopausal osteoporotic vertebral fractures: Increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures Osteopor Int 13 2002 158 170
    • (2002) Osteopor Int , vol.13 , pp. 158-170
    • Guteridge, D.H.1    Stewart, G.O.2    Prince, R.L.3
  • 19
    • 0035985563 scopus 로고    scopus 로고
    • Monofluorphosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study
    • J.D. Ringe, and I. Setnikar Monofluorphosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study Rheumatol Int 22 2002 27 32
    • (2002) Rheumatol Int , vol.22 , pp. 27-32
    • Ringe, J.D.1    Setnikar, I.2
  • 20
    • 0030787827 scopus 로고    scopus 로고
    • Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?
    • W.F. Lems, J.W.G. Jacobs, and J.W.J. Bijlsma Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheumatol Dis 56 1997 357 363
    • (1997) Ann Rheumatol Dis , vol.56 , pp. 357-363
    • Lems, W.F.1    Jacobs, J.W.G.2    Bijlsma, J.W.J.3
  • 21
    • 0141573538 scopus 로고    scopus 로고
    • Parathyroid hormone plus alendronate. a combination that does not add up
    • S. Khosla Parathyroid hormone plus alendronate. A combination that does not add up N Eng J Med 349 2003 1277 1279
    • (2003) N Eng J Med , vol.349 , pp. 1277-1279
    • Khosla, S.1
  • 22
    • 0035461379 scopus 로고    scopus 로고
    • Reconstructing the skeleton with intermittent parathyroid hormone
    • E. Seeman, and P.D. Delmas Reconstructing the skeleton with intermittent parathyroid hormone Trends Enocrinol Metab 12 2001 281 283
    • (2001) Trends Enocrinol Metab , vol.12 , pp. 281-283
    • Seeman, E.1    Delmas, P.D.2
  • 23
    • 0024549034 scopus 로고    scopus 로고
    • Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients
    • R.D. Hesch, U. Busch, M. Prokop, G. Delling, and E.F. Rittinghaus Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients Calcif Tissue Int 44 1998 176 180
    • (1998) Calcif Tissue Int , vol.44 , pp. 176-180
    • Hesch, R.D.1    Busch, U.2    Prokop, M.3    Delling, G.4    Rittinghaus, E.F.5
  • 24
    • 0031024187 scopus 로고    scopus 로고
    • A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis
    • A.B. Hodsman, L.J. Fraher, and P.H. Watson A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis J Clin Endocrinol Metab 82 1997 620 628
    • (1997) J Clin Endocrinol Metab , vol.82 , pp. 620-628
    • Hodsman, A.B.1    Fraher, L.J.2    Watson, P.H.3
  • 25
    • 0030804947 scopus 로고    scopus 로고
    • Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
    • R. Lindsay, J. Nieves, and C. Formica Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis Lancet 350 1997 550 555
    • (1997) Lancet , vol.350 , pp. 550-555
    • Lindsay, R.1    Nieves, J.2    Formica, C.3
  • 26
    • 0035063315 scopus 로고    scopus 로고
    • Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal
    • F. Cosman, J. Nieves, and L. Woelfert Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal J Bone Miner Res 16 2001 925 931
    • (2001) J Bone Miner Res , vol.16 , pp. 925-931
    • Cosman, F.1    Nieves, J.2    Woelfert, L.3
  • 27
    • 1642401284 scopus 로고    scopus 로고
    • Treatment of osteoporosis: Why, whom, when, and how to treat. the single most important consideration is the individual's absolute risk of fracture
    • E. Seeman, and J.A. Eisman Treatment of osteoporosis: why, whom, when, and how to treat. The single most important consideration is the individual's absolute risk of fracture Med J Aust 180 2004 298 303
    • (2004) Med J Aust , vol.180 , pp. 298-303
    • Seeman, E.1    Eisman, J.A.2
  • 28
    • 0031802037 scopus 로고    scopus 로고
    • Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women
    • F. Cosman, J. Nieves, L. Woelfert, V. Shen, and R. Lindsay Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women J Bone Miner Res 13 1998 1051 1055
    • (1998) J Bone Miner Res , vol.13 , pp. 1051-1055
    • Cosman, F.1    Nieves, J.2    Woelfert, L.3    Shen, V.4    Lindsay, R.5
  • 29
    • 0141684971 scopus 로고    scopus 로고
    • The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
    • for the PaTH study investigators K.E.
    • D.M. Black, S.L. Greenspan, K.E. Ensrud for the PaTH study investigators The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N Eng J Med 349 2003 1207 1215
    • (2003) N Eng J Med , vol.349 , pp. 1207-1215
    • Black, D.M.1    Greenspan, S.L.2    Ensrud3
  • 30
  • 31
    • 0346096737 scopus 로고    scopus 로고
    • Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis
    • Letters to the Editor.
    • Letters to the Editor. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. N Eng J Med 2004; 350:189-192.
    • (2004) N Eng J Med , vol.350 , pp. 189-192
  • 32
    • 1342329523 scopus 로고    scopus 로고
    • Does bone resorption inhibition affect the anabolic response to parathyroid hormone?
    • T.J. Martin Does bone resorption inhibition affect the anabolic response to parathyroid hormone? Trends Endocrinol Metab 15 2004 49 50
    • (2004) Trends Endocrinol Metab , vol.15 , pp. 49-50
    • Martin, T.J.1
  • 33
    • 3242762388 scopus 로고    scopus 로고
    • Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
    • B. Ettinger, J. San Martín, G. Grans, and I. Pavo Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate J Bone Miner Res 19 2004 745 751
    • (2004) J Bone Miner Res , vol.19 , pp. 745-751
    • Ettinger, B.1    San Martín, J.2    Grans, G.3    Pavo, I.4
  • 34
    • 0026167127 scopus 로고
    • HPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses
    • J. Reeve, J.E. Bradbeer, and M. Arlot hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses Osteopor Int 1 1991 162 170
    • (1991) Osteopor Int , vol.1 , pp. 162-170
    • Reeve, J.1    Bradbeer, J.E.2    Arlot, M.3
  • 35
    • 0034458020 scopus 로고    scopus 로고
    • Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate
    • R.S. Rittmaster, M. Bolognes, and M.P. Ettinger Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate J Clin Endocrinol Metab 85 2000 2129 2134
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 2129-2134
    • Rittmaster, R.S.1    Bolognes, M.2    Ettinger, M.P.3
  • 36
    • 4544266340 scopus 로고    scopus 로고
    • The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34)]
    • E.S. Kurland, S.L. Heller, B. Diamond, D.J. McMahon, F. Cosman, and J.P. Bilezikian The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34)] Osteopor Int 15 2004 992 997
    • (2004) Osteopor Int , vol.15 , pp. 992-997
    • Kurland, E.S.1    Heller, S.L.2    Diamond, B.3    McMahon, D.J.4    Cosman, F.5    Bilezikian, J.P.6
  • 37
    • 0035837553 scopus 로고    scopus 로고
    • Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
    • R.M. Neer, C.D. Arnaud, and J.R. Zanchetta Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 2001 1434 1441
    • (2001) N Engl J Med , vol.344 , pp. 1434-1441
    • Neer, R.M.1    Arnaud, C.D.2    Zanchetta, J.R.3
  • 38
    • 6344278780 scopus 로고    scopus 로고
    • Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis
    • R. Lindsay, W.H. Scheele, and R. Neer Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis Arch Intern Med 164 2004 2024 2030
    • (2004) Arch Intern Med , vol.164 , pp. 2024-2030
    • Lindsay, R.1    Scheele, W.H.2    Neer, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.